Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Coya Therapeutics, Inc.COYA · Entity 6727 | Chief Medical Officer | February 27, 2023 | March 01, 2023 |
| EAGLE PHARMACEUTICALS, INC.EGRX · Entity 85958 | EVP and Chief Medical Officer | January 23, 2020 | January 27, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Coya Therapeutics, Inc.
Report date February 27, 2023 · Filed March 01, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.85 · Expires 2033-02-27 | Direct | 115,000 |
Reported balance
After 2023-02-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-27 · Grant · Acquired 115,000 · Balance 115,000 F1: Subject to continuous service, the shares subject to the option vest in equal monthly installments over a period of 36 months commencing on March 27, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to continuous service, the shares subject to the option vest in equal monthly installments over a period of 36 months commencing on March 27, 2023.
EAGLE PHARMACEUTICALS, INC.
Report date January 23, 2020 · Filed January 27, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 48,784 |
Reported balance
After 2020-01-23 transaction · row 1
1 source rowRow 1 · 2020-01-23 · Tax withholding · Disposed 1,630 · Balance 48,784 F1: Represents shares withheld to satisfy withholding tax obligations. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld to satisfy withholding tax obligations.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2023 Filed Mar 1, 2023 16:05 UTC | Coya Therapeutics, Inc. COYA · Entity 6727 | GrantStock Option (right to buy) · Derivative | 115,000 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001493152-23-006390 · ownership.xml · derivative · entry 1 Hepner Adrian · CIK 0001637347 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2033-02-27 F1 · derivative.exercise_date: Subject to continuous service, the shares subject to the option vest in equal monthly installments over a period of 36 months commencing on March 27, 2023. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 08:30 UTC | Coya Therapeutics, Inc. COYA · Entity 6727 | PurchaseWarrant to Purchase Common Stock · Derivative | 5,000 | Not disclosed Strike: $7.50 | Not disclosed |
DisclosureSEC source: 0001493152-23-000225 · ownership.xml · derivative · entry 2 Hepner Adrian · CIK 0001637347 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock, par value $0.0001 per share · 5,000 shares Expires 2025-01-03 F1 · price: Reporting Person purchased 10,000 shares of Common Stock and an accompanying warrant to purchase 5,000 shares of Common Stock in the Issuer's initial public offering at a combined purchase price of $5.00 per share and accompanying warrant. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 08:30 UTC | Coya Therapeutics, Inc. COYA · Entity 6727 | PurchaseCommon Stock, par value $0.0001 per share | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-23-000225 · ownership.xml · nonDerivative · entry 1 Hepner Adrian · CIK 0001637347 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: Reporting Person purchased 10,000 shares of Common Stock and an accompanying warrant to purchase 5,000 shares of Common Stock in the Issuer's initial public offering at a combined purchase price of $5.00 per share and accompanying warrant. Read SEC document |
| January 23, 2020 Filed Jan 27, 2020 16:13 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | Tax withholdingCommon Stock | 1,630 | $57.98 | $94,507.40 |
DisclosureSEC source: 0001209191-20-004986 · doc4.xml · nonDerivative · entry 1 Hepner Adrian · CIK 0001637347 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,784 F1 · kind: Represents shares withheld to satisfy withholding tax obligations. Read SEC document |
| January 07, 2020 Filed Jan 7, 2020 18:22 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | Tax withholdingCommon Stock | 815 | $57.38 | $46,764.70 |
DisclosureSEC source: 0001209191-20-002345 · doc4.xml · nonDerivative · entry 2 Hepner Adrian · CIK 0001637347 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,414 F3 · kind: Represents shares withheld to satisfy withholding tax obligations. Read SEC document |
| January 05, 2020 Filed Jan 7, 2020 18:22 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | GrantEmployee Stock Option (right to buy) · Derivative | 55,000 | $0.00 Strike: $59.80 | $0.00 |
DisclosureSEC source: 0001209191-20-002345 · doc4.xml · derivative · entry 3 Hepner Adrian · CIK 0001637347 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2030-01-04 F4 · derivative.exercise_date: The option vests over a period of four years, with 25% of the shares underlying the option vesting on January 5, 2021, the first anniversary of the date of grant, and the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. Read SEC document |
| January 05, 2020 Filed Jan 7, 2020 18:22 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | GrantCommon Stock | 24,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-002345 · doc4.xml · nonDerivative · entry 1 Hepner Adrian · CIK 0001637347 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,229 F1 · shares: Represents restricted stock units ("RSUs"). The RSUs vest over a period of four years, with 25% of the RSUs vesting on each of the one, two, three and four-year anniversaries of January 5, 2020, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 20:04 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | GrantEmployee Stock Option (right to buy) · Derivative | 42,500 | $0.00 Strike: $42.40 | $0.00 |
DisclosureSEC source: 0001209191-19-005443 · doc4.xml · derivative · entry 3 Hepner Adrian · CIK 0001637347 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,500 Underlying: Common Stock · 42,500 shares Expires 2029-01-23 F4 · derivative.exercise_date: The option vests over a period of four years, with 25% of the shares underlying the option vesting on January 23, 2020, the first anniversary of the date of grant, and the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 20:04 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | GrantCommon Stock | 19,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-005443 · doc4.xml · nonDerivative · entry 2 Hepner Adrian · CIK 0001637347 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,229 F2 · shares: Represents restricted stock units ("RSUs"). The RSUs vest over a period of four years, with 25% of the RSUs vesting on each of the one, two, three and four-year anniversaries of January 23, 2019, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. F3 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 07, 2019 Filed Jan 25, 2019 20:04 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | Tax withholdingCommon Stock | 771 | $41.33 | $31,865.43 |
DisclosureSEC source: 0001209191-19-005443 · doc4.xml · nonDerivative · entry 1 Hepner Adrian · CIK 0001637347 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,229 F1 · kind: Represents shares withheld to satisfy withholding tax obligations. Read SEC document |
| January 07, 2018 Filed Jan 9, 2018 17:44 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | GrantPerformance Stock Unit · Derivative | 27,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-002995 · doc4.xml · derivative · entry 3 Hepner Adrian · CIK 0001637347 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2021-01-01 F3 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's common stock. F4 · shares: Represents the maximum number of shares issuable under this award. F5 · derivative.exercise_date: The shares issuable in respect of such PSUs shall vest on the three-year anniversary of January 1, 2018 (such three-year anniversary, the "Vesting Date"), based on the extent to which the following stock price hurdles are achieved for 30 consecutive trading days on or prior to the Vesting Date. If the Issuer's stock price reaches or surpasses $85.92, $110.00, $120.00 or $134.25, then 9,000, 18,000, 22,500 or 27,000 PSUs will vest, respectively. The number of shares issuable in respect of such PSUs vested on the Vesting Date will be determined by the highest Issuer stock price hurdle achieved. This vesting is subject to the Reporting Person's continuous service with the Issuer as of the Vesting Date. Read SEC document |
| January 07, 2018 Filed Jan 9, 2018 17:44 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | GrantEmployee Stock Option (Right to Buy) · Derivative | 43,000 | $0.00 Strike: $59.14 | $0.00 |
DisclosureSEC source: 0001209191-18-002995 · doc4.xml · derivative · entry 2 Hepner Adrian · CIK 0001637347 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,000 Underlying: Common Stock · 43,000 shares Expires 2028-01-06 F2 · derivative.exercise_date: The option vests over a period of four years, with 25% of the shares underlying the option vesting on January 7, 2019, the first anniversary of the date of grant, and the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. Read SEC document |
| January 07, 2018 Filed Jan 9, 2018 17:44 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | GrantCommon Stock | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-002995 · doc4.xml · nonDerivative · entry 1 Hepner Adrian · CIK 0001637347 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 F1 · shares: These shares were issued pursuant to a restricted stock unit ("RSU") award, each RSU representing a contingent right to receive one share of the Issuer's common stock. The shares issuable in respect of such RSUs shall vest with respect to 25% of the shares of common stock on each of the one, two, three and four-year anniversaries of January 7, 2018, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 17:05 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | GrantStock Option (right to buy) · Derivative | 67,200 | $0.00 Strike: $84.92 | $0.00 |
DisclosureSEC source: 0001209191-17-002683 · doc4.xml · derivative · entry 1 Hepner Adrian · CIK 0001637347 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,200 Underlying: Common Stock · 67,200 shares Expires 2027-01-03 F1 · derivative.exercise_date: The option vests over a period of four years, with 25% of the shares underlying the option vesting on January 4, 2018, the first anniversary of the date of grant, and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.